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Abstract
Background: Pre-clinical studies suggest that metformin and statins may delay prostate cancer (PCa) metastases; however, data in humans are limited. To the best of our
knowledge, this is the first human study aimed to quantify the individual and joint
effects of statin and metformin use among patients with high-risk PCa.
Methods: This population-based retrospective cohort study identified patients from
the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database.
Exposure to metformin and statins was ascertained from Medicare Prescription Drug
Event files. The association with all-cause and PCa mortality were evaluated using
Cox proportional hazard model with competing causes of death, where propensity
scores were used to adjusted imbalances in covariates across groups.
Results: Based on 12 700 patients with high-risk PCa, statin alone or in combination with metformin was significantly associated with reduced all-cause mortality
(Hazard Ratio [HR]: 0.89; 95% Confidence Interval [CI]: 0.83, 0.96; and HR: 0.75;
95% CI, 0.67-0.83, respectively) and PCa mortality (HR, 0.80; 95% CI: 0.69, 0.92)
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and 0.64; 95% CI, d 0.51-0.81, respectively. The effects were more pronounced in
post-diagnostic users: combination use of metformin/statins was associated with a
32% reduction in all-cause mortality (95% CI, 0.57-0.80), and 54% reduction in PCa
mortality (95% CI, 0.30-0.69). No significant association of metformin alone was
observed with either all-cause mortality or PCa mortality.
Conclusions: Statin use alone or in combination with metformin was associated with
lower all-cause and PCa mortality among high-risk patients, particularly in post-diagnostic settings; further studies are warranted.
KEYWORDS
all-cause mortality, high-risk prostate cancer, metformin, population-based cohort, prostate-cancer
mortality, statins, time-varying Cox proportional hazard models
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IN TRO D U C T ION

Approximately 15% of patients diagnosed with prostate cancer (PCa) patients have high-risk PCa as defined by ≥T2c,
or PSA ≥20, or Gleason Score ≥8.1 Patients with high-risk
PCa have a significant chance of developing systemic or local
recurrence and are at higher risk of death from the disease.
Therefore, thus, tremendous attempts to further reduce PCa
mortality are directed at these patients. The majority of patients with PCa who later develop lethal metastatic disease
have high-risk localized disease at presentation, also emphasizing the importance of effective treatment strategies at this
stage.2 Identifying or developing additional therapies with
low toxicity and cost is important to improve longevity and
quality of life of men diagnosed with high-risk PCa.
Evidence suggests that two widely prescribed drugs with
established safety profiles, metformin and statins, have promising anti-cancer effects and are associated with lower mortality in PCa patients.3,4 Several epidemiologic studies have
investigated the effects of individual use of metformin and
statins on PCa incidence and mortality.5-9 Recently, pre-clinical data indicated a combination of metformin and statin
was better than either drug alone in inhibiting primary tumor
growth, metastasis to bone, and biochemical failure; human
data on the joint effects of statins and metformin on PCa
mortality are limited.10,11 Because the majority of metformin
users also take statins12,13 some of the favorable outcomes observed among metformin users might be derived from statins.
It is essential to distinguish the individual and joint effects
of statins and metformin to further understand their potential
synergistic role in cancer, explore alternative therapeutics for
preventing PCa progression, and to inform future trial design.
The primary objective of this study was to quantify the individual and joint effects of metformin and statins on all-cause
and PCa mortality, and to test the hypothesis that a combination of metformin and statin is associated with lower allcause and PCa mortality among high-risk patients. In order

to understand the role of statins or metformin in an adjuvant
setting, we specifically sought to quantify the individual and
joint effects of statins and metformin in post-diagnostic settings (ie, medications initiated after PCa diagnosis).

2
2.1

|

M ATERIAL S AND M ETHOD S

|

Data sources and study participants

We used data from the Surveillance, Epidemiology, and End
Results (SEER-18) database linked with Medicare files. The
SEER program covers about 28% of the US population, collects information on newly diagnosed cancer patients living
in predefined US geographical areas, with about 98% ascertainment rate.14
Our study includes patients diagnosed with cancer through
2011, and Part D data 2007-2012. To allow a 1-year window
before or after cancer diagnosis for baseline assessment of
comorbidities and use of prescriptions, we selected patients
with high-risk PCa being diagnosed from January 2008 to
December 2011 (Figures 1 and 2).
Primary PCa cases were identified using the International
Classification of Disease for Oncology, Third Edition (ICDO-3) histology codes (https
://seer.cancer.gov/icd-o-3/).
Patients were excluded if enrolled in health-care maintenance
organizations, diagnosed at autopsy, missing a diagnosis date,
or had a death date equal to or less than the diagnosis date.
To ensure that Medicare claims were available for all participants, we included patients who were continuously enrolled
in Medicare Part A and B during the study period (January
2007 to February 2014). To capture the potential drug effect up to 3 months before cancer diagnosis, we further restricted our study to those who were continuously enrolled
in Medicare Part D beginning at least 3 months prior cancer
diagnosis until death or December 31, 2012, the last date of
available Part D data. All patients were assigned into low-,

  

TAN et al.

123 578 prostate cancer patients ≥ 65 years of age
reported to SEER in 2008 -2011
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Excluding patients diagnosed at autopsy (N = 2507) and
patients with different month of death in SEER and Medicare
(N = 151)

(N = 2658)
120 920 prostate cancer patients with known diagnosis
and death time

Excluding patients who were not continuously enrolled in
Medicare Part A and B during the study period (N = 20 472),
and patients who were not enrolled in Part D from 3 months
before diagnosis to death or February 15, 2014 (N = 43 250)

(N = 63 722)
57 198 prostate cancer patients with continuous
enrollment in Medicare Part A, B and D
(N = 43 453)

Excluding patients who are not high-risk of prostate cancer

13 745 high-risk prostate cancer patients (T category ≥
T2c or PSA level ≥ 20 or Gleason score ≥ 8)
(N = 1045)

Excluding patients who survived less than for 6 months

12 700 high risk prostate cancer patients survived at
least for 6 months
FIGURE 1

Selection of patients diagnosed with primary high-risk prostate cancer in SEER 2008-2011

Date of Part D
available
January 01, 2007

Neither user

1st date of CaP
diagnosis
January 15, 2008

Metformin user

Starting date
of metformin
July 5, 2009

Last follow -up

One year look-back
window of baseline
assessment for
comorbidities,
procedures, and use
of prescription

Cohort entry

Follow-up period

Dual user

Starting date of
metformin and
statin
June 10, 2010

Date of:
• Death
• Last date of study
(February 15, 2014)

F I G U R E 2 Timeline of a patient's baseline status and exposure through the study. The follow-up starts on the date of prostate cancer
diagnosis, January 15, 2008 (cohort entry date). The 1-yr look-back period for comorbidities, procedures, and use of prescription started on January
1, 2007. The end of follow-up date is February 15, 2014

intermediate-, or high-risk groups based on D'Amico classification system.15 We selectively focused on high-risk PCa
(T category ≥T2c or prostate specific antigen level ≥20 or
Gleason score ≥8; equivalent to overall cancer stage ≥IIB),
because evidence regarding statin effects are most consistent
for advanced PCa.3 Moreover, because the follow-up time of
this study was relatively short, precise estimates of PCa mortality endpoints could be reached in high-risk patients only.
To account for latency effects and minimize healthy user effect (statins are usually discontinued in individuals with short
life expectancy), we further restricted our study to those
who survived at least 6 months. The study was conducted

in accordance with a SEER-Medicare data use agreement
and approved by the Institutional Review Board at Rutgers
University.

2.2

|

Metformin and statin exposures

To determine metformin and statin exposures, Part D prescription drug event files were used. These files include information on drug name, dispensation dates, dosage, and days’
supply for each prescription. We defined post-diagnostic
users as patients who had their first documented prescription

4
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of study medication after the PCa diagnosis. Patients who
had first documented prescription of study medication before
the PCa diagnosis and continuously used the drug after diagnosis were considered pre-diagnostic users. Statins were
categorized based on the following drug characteristics: lipophilic (atorvastatin, fluvastatin, lovastatin, and simvastatin); hydrophilic (pravastatin and rosuvastatin); high potency
(atorvastatin, rosuvastatin, and simvastatin); or low potency
(fluvastatin, lovastatin, and pravastatin).16

2.3 | Assessment of covariates and
study outcomes
Information was extracted on age, race, marital status, region,
year of diagnosis, state buy-in (for individual with limited income and resources, the state pays part or all of the patient's
Medicare Part B premium or the person is in the Medicaid
program), as well as contextual data on socioeconomic status
including income and education. To avoid overestimating comorbidity as a result of PCa diagnosis, the Charlson score was
based on diagnosis codes from 11 months prior to cancer diagnosis.17 Receipt of primary cancer therapy was ascertained
within 1 year of cancer diagnosis,18 and the presence of secondary cancer therapy was ascertained if patients switched to other
cancer therapies after a period of primary therapy.
The primary endpoints were all-cause and PCa mortality.
Data on all-cause and PCa mortality were based on SEER records available through February 15, 2014 and December 15,
2011, respectively (Figure 2). Causes of PCa death in the SEER
record were based on the underlying causes of death in the
death certificate, which had a high agreement (87%-92%) with
medical record review.19 Patients were censored at death, last
contact, or the last date of available data for endpoints.

2.4

|

Statistical analyses

Descriptive statistics with Chi-square tests were used to estimate the differences on demographic and clinical characteristics. Propensity scores 20 were used to estimate the probability
of one of the following four exclusive medication use categories: “ever used statin” (p1), “ever used metformin” (p2), “ever
used both statin and metformin” (p3) and “none.” They were
calculated based on patients’ sociodemographic characteristics,
and comorbidities (Charlson Comorbidity Score, diabetes, obesity/metabolic syndrome, and hyperlipidemia) using a general
(polytomous) logistic regression model.21 To control pre-treatment imbalances on observed variables, propensity scores p1,
p2, and p3 were included as covariates in the statistical models for propensity score adjustment. Cox proportional hazards
models (with competing causes of death) were used to estimate
hazards ratios (HRs) and 95% confidence intervals (CIs).22,23

The association between metformin and/or statin use and
all-cause and PCa mortality was evaluated by sequentially
adding the following variables: (a) demographic characteristics; (b) tumor characteristics; (c) treatment characteristics;
(d) comorbidities, and (e) Charlson Comorbidity Score. We
developed the final model by adjusting for cancer stage, primary cancer therapy (surgery, radiotherapy, androgen deprivation therapy [ADT]), secondary cancer therapy, salvage
radiation, and propensity scores, as well as the variables that
remained imbalanced after propensity score adjustment (ie,
age, Charlson Score, diabetes, dyslipidemia, diabetes/IGT).
Cancer stage were grouped based on five key components
(T category, N category, M category, PSA level and Gleason
core) using the American Joint Committee on Cancer TNM
staging system. We included overall cancer stage instead
of individual component to reduce a large number of variables in Cox models. For all of the models we considered,
the proportional hazards assumption was evaluated using
Schoenfeld residual plots.24 All analyses were two-tailed
test based on α = 0.05 and conducted using SAS Version 9.4
(SAS Institute).

|

2.5

Sensitivity and subgroup analyses

According to the new National Comprehensive Cancer
Network risk criteria,25 patients with a clinical stage of T2c
were no longer considered to have high-risk PCa. Therefore,
we performed a sensitivity analysis using the study population
including all patients with clinical stage ≥T3a, or Gleason
score ≥8, or PSA ≥20 ng/mL. To address potential healthy
user effects and latency for analyses of post-diagnostic statin
use, we restricted our study to those who survived at least for
6 months. However, potential bias could result from excluding the sickest cases for analyses of pre-diagnostic statin use,
we further performed a sensitivity analysis by including the
patients with survival less than 6 months. Additionally, it is
important to know whether the drug effect varies with patient
characteristics, other cancer therapies received, or other prognostic factors; therefore, we carried out multiple pre-planned
sub-analyses by: (a) primary cancer therapy; (b) presence of
secondary cancer therapy, suggesting that the patients have
failed primary cancer therapy; (c) cancer stage and M categories; (d) statin name, type, and potency; and (e) presence of
documented obesity or other major comorbidities.

3
3.1

|

RESULTS

|

Baseline characteristics

The study cohort consisted of 12 700 high-risk PCa patients
who were diagnosed between 2008 and 2011, and survived
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at least for 6 months. The median age at diagnosis was
74 years (quartiles: 70-80). During a median follow-up of
42 months (quartiles: 26.4-57.6), 2182 (17.2%) patients died
from any cause and 1078 (8.5%) died from prostate cancer.
Most metformin users took statins (1911/2346 = 81%, Table
1). Compared to those who did not use statins or metformin,
users of metformin alone, statin alone, and their combination
were significantly younger and more likely to have diabetes, obesity or metabolic syndrome, and hyperlipidemia, and
had a higher Charlson score with less advanced-stage cancer
(Table 1).

3.2

|

Survival outcomes

Median survival was 3.1 years with metformin, 3.6 with
statins, and 3.9 with metformin plus statin, vs 3.1 years for
those who did not use either drug. Based on Cox models,
metformin plus statin (HR, 0.75; 95% CI, 0.67-0.83) and statin alone (HR, 0.89; 95% CI, 0.83-0.96) were significantly associated with a lower all-cause mortality, after adjusting for
potential confounders (Table 2). With respect to PCa mortality, metformin plus statin was associated with a 36% risk
reduction (95% CI, 0.54-0.85), followed by statin alone (HR,
0.80; 95% CI, 0.69-0.92) (Table 2). Metformin alone was
relatively rare, and there was no significant association with
all-cause mortality (HR, 0.89; 95% CI, 0.75-1.05) (Table 2),
and PCa mortality (HR, 0.75; 95% CI, 0.53-1.05) (Table 2).
To provide insight about the potential impact in an adjuvant setting, we examined the differential effects among
pre-diagnostic and post-diagnostic users. The effects of statin
alone or combination of metformin and statin on both allcause and PCa mortality are more pronounced in post-diagnostic users. Among post-diagnostic users, statin alone was
significantly associated with a 27% reduction in all-cause
mortality (95% CI, 0.64-0.84) and a 42% reduction in PCa
mortality, compared to those who did not use statins or metformin. Metformin plus statins was associated with a 32%
reduction in all-cause mortality (95% CI, 0.57-0.80), and a
54% reduction in PCa mortality (95% CI, 0.30-0.69) (Table
2). Again, metformin alone did not show any significant effects on all-cause mortality and PCa mortality among either
pre-diagnostic or post-diagnostic users (Table 2).

3.3

|

Sensitivity and subgroup analyses

We first performed sensitivity analyses by using the study
population including all patients with clinical stage ≥T3a,
or Gleason score ≥8, or PSA ≥20 ng/mL. Similar HRs of
all-causes and PCa mortality were observed for metformin
and/or statin use (data not shown). Therefore all of the following subgroup analyses were performed using the study

|
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population that included all patients with clinical stage ≥T2c,
or Gleason score ≥8, or PSA ≥20 ng/mL. We also performed
sensitivity analyses by including the patients with survival
less than 6 months, and a similar pattern of the results with
even lower HRs were observed (data not shown).
To assess the impact of disease extent on observed drug
effects, we stratified medication use by disease extent (ie,
cancer stage, M categories), and found no significant effect modification for both all-cause and PCa mortality
(Pinteraction > .05) (Table S1). Among patients with Stage IV
PCa, data suggest there might be some synergistic effect between statin and metformin (HR, 0.93 for metformin alone,
0.82 for statin alone, and 0.66 for metformin plus statin) although this interaction did not reach statistical significance
(Pinteraction = .18) (Table S1).
To assess the impact of existing health conditions on observed drug effects, we carried out pre-planned sub-analyses
by the status of diabetes, dyslipidemia, or obesity/metabolic
syndrome. We found that diabetes and dyslipidemia significantly modified the effects of statin alone or metformin plus
statin on all-cause mortality (Pinteraction < .0001), but not on
PCa mortality (Pinteraction ≥ .05) (Table S2). No significant
effect modification of obesity/metabolic syndrome was observed for both all-cause and PCa mortality (Pinteraction > .05)
(Table S2). To evaluate the effect modification of cancer
treatment, we stratified by the status of primary and secondary cancer therapy as well as salvage radiation, we observed
no evidence that they modified the effects of metformin and
statins (Pinteraction > .05) (Tables S3 and S4). To account for
the healthy user effects, we further stratified by Charlson
score, and found no significant effect modification for both
all-cause and PCa mortality (Pinteraction > .05) (Table S5).
Further pre-planned sub-analyses revealed that among
statins, only lovastatin was not significantly associated with
the reduction in PCa mortality (HR, 0.92; 95% CI, 0.76-1.12)
(Table 3). The effects of lipophilic vs hydrophilic and high vs
low potency statins were not statistically different (Table 3).

4
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DISCUSSION

Both metformin and statins are individually associated with
reduction in PCa mortality and the use of both medications
together is common.3,4 To the best of our knowledge, this is
the first major epidemiological study to quantify individual
and joint effects of metformin and statin on all-cause and PCa
mortality among high-risk PCa patients. We found that both
statin alone and a combination of metformin and statin was
significantly associated with reduced all-cause and PCa mortality. The effect of combination use of metformin and statin was particularly substantial among post-diagnostic users
with high-risk PCa (54% reduction in PCa mortality) despite
the relatively short follow-up time. Based on the existing
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Demographic, clinical, and comorbid characteristics
No. (%) of patients

Variables

Overall
(n = 12,700)

No metformin/no statin
(n = 4568)

Metformin
alone
(n = 435)

Statin alone
(n = 5786)

Metformin+statin
(n = 1911)

Age
65-69

3123 (25)

1117 (24)

122 (28)*

1328 (23)**

70-79

6344 (50)

2150 (47)

218 (50)

2938 (51)

1038 (54)

3233 (25)

1301 (28)

95 (22)

1520 (26)

317 (17)

No

3307 (26)

1300 (28)

117 (27)

1436 (25)**

454 (24)**

Yes

7806 (61)

2696 (59)

258 (59)

3653 (63)

1199 (63)

Unknown

1587 (12)

572 (13)

60 (14)

697 (12)

258 (14)

Marital status

Race
White

9805 (77)

3495 (77)

307 (71)*

4597 (79)**

1406 (74)**

Black

1652 (13)

678 (15)

77 (18)

619 (11)

278 (15)

Others

1243 (10)

395 (9)

51 (12)

570 (10)

227 (12)

Region
1651 (13)

569 (12)

60 (14)

781 (14)*

South

2625 (21)

970 (21)

113 (26)

1123 (19)

419 (22)

1146 (9)

445 (10)

37 (9)

501 (9)

163 (9)

West

7278 (57)

2584 (57)

225 (52)

3381 (58)

1088 (57)

Educationa
4079 (32)

1451 (34)

102 (23)**

1997 (35)**

80%-92%

4556 (36)

1656 (36)

173 (40)

2025 (35)

702 (37)

3434 (27)

1249 (27)

134 (31)

1457 (25)

594 (32)

Unknown

631 (5)

212 (5)

26 (6)

307 (5)

86 (5)

Median income
3833 (30)

1459 (32)

155 (36)*

1603 (28)**

$45000-$70 000

4238 (33)

1504 (33)

154 (35)

1908 (33)

672 (35)

4021 (32)

1401 (31)

101 (23)

1980 (34)

539 (28)

Unknown

608 (5)

204 (4)

25 (6)

295 (5)

84 (4)

Year of diagnosis
4028 (32)

1407 (31)

142 (33)

1829 (32)*

.98

<.01

.96

<.01

.72

<.01

.73

<.01

.86

<.01

.97

<.01

.54

<.01

.03

<.01

<.01

650 (34)*

2009

3734 (29)

1298 (28)

116 (27)

1771 (31)

549 (29)

2010

2529 (20)

939 (21)

82 (19)

1127 (19)

381 (20)

2011

2409 (19)

924 (20)

95 (22)

1059 (19)

331 (17)

State buy-inb
No

9542 (75)

3407 (75)

300 (69)*

4503 (78)**

1332 (70)**

Yes

3158 (25)

1161 (25)

135 (31)

1283 (22)

579 (30)

Charlson scorec
0

7970 (63)

3426 (75)

207 (48)**

3568 (62)**

769 (40)**

1

2004 (16)

567 (12)

114 (26)

926 (16)

397 (21)

2+

2726 (21)

575 (13)

114 (26)

1292 (22)

745 (39)

6928 (55)

3244 (71)

65 (15)**

3375 (58)**

244 (13)**

Diabetes
No

<.01

616 (32)

>$70 000

2008

.04

529 (28)**

< 80%

≤$45 000

<.01

241 (13)

North central

>92%

Adjusted
Pe

556 (29)**

80+

Northeast

P

(Continues)

  

TAN et al.

TABLE 1

|

7

(Continued)
No. (%) of patients

Variables
Yes

Overall
(n = 12,700)

No metformin/no statin
(n = 4568)

Metformin
alone
(n = 435)

Statin alone
(n = 5786)

Metformin+statin
(n = 1911)

5772 (45)

1324 (29)

370 (85)

2411 (42)

1667 (87)

Obesity/metabolic syndrome
No

10 806 (85)

4123 (90)

356 (82)**

4924 (85)**

1403 (73)**

Yes

1894 (15)

445 (10)

79 (18)

862 (15)

508 (27)

Hyperlipidemia
No

4316 (34)

2653 (58)

187 (43)**

1138 (20)**

338 (18)**

Yes

8384 (66)

1915 (42)

248 (57)

4648 (80)

1576 (82)

Cancer stage
IIB

8546 (67)

2902 (64)

270 (62)

4023 (70)**

1351 (71)**

III

1259 (10)

457 (10)

53 (12)

559 (10)

190 (10)

IV

2895 (23)

1209 (26)

112 (26)

1204 (21)

370 (19)

9646 (76)

3281 (72)

309 (71)

4542 (78)**

1513 (79)**

M categories
M0
M1

2412 (19)

1066 (23)

101 (22)

942 (16)

303 (16)

Unknown

642 (5)

221 (5)

25 (5)

302 (5)

95 (5)

Lymph notes
No

10 283 (81)

3598 (79)**

336 (77)**

4773 (82)**

1576 (82)**

Yes

971 (8)

390 (9)

44 (10)

407 (7)

130 (7)

Missing

1446 (11)

580 (13)

55 (13)

606 (10)

205 (11)

Androgen deprivation therapyd
No

8279 (65)

2980 (65)

250 (57)**

3829 (66)

1220 (64)

Yes

4421 (35)

1588 (35)

185 (43)

1957 (34)

691 (36)

Radiation therapyd
No

9535 (75)

3581 (78)

316 (73)**

4278 (74)**

1360 (71)**

Yes

3165 (25)

987 (22)

119 (27)

1508 (26)

551 (29)

12 176 (96)

4374 (96)

418 (96)

5561 (96)

1823 (95)

524 (4)

194 (4)

17 (4)

225 (4)

88 (5)

No

10 890 (86)

4000 (88)

389 (89)

4873 (84)**

1628 (85)**

Yes

1810 (14)

568 (12)

46 (11)

913 (16)

183 (15)

Chemotherapyd
No
Yes
Surgery

d

Salvage radiation
No

12 356 (97)

4458 (98)

419 (96)

5612 (97)

1867 (98)

Yes

344 (3)

110 (2)

16 (4)

174 (3)

44 (2)

Secondary therapy
No

9297 (73)

3457 (76)**

304 (70)**

4211 (73)**

1325 (69)**

Yes

3403 (27)

1111 (24)

131 (30)

1575 (27)

586 (31)

Gleason categories
<8

2293 (18)

788 (17)

57 (13)**

1082 (19)

366 (19)

8

2322 (18)

743 (16)

82 (19)

1128 (19)

369 (19)

>8

2042 (16)

687 (15)

74 (17)

943 (16)

338 (18)

P

Adjusted
Pe

<.01

.01

<.01

<.01

<.01

NC

<.01

NC

<.01

NC

<.01

NC

<.01

NC

.54

NC

<.01

NC

.08

NC

<.01

NC

<.01

.17

(Continues)
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(Continued)
No. (%) of patients

Variables
Missing

Overall
(n = 12,700)

No metformin/no statin
(n = 4568)

Metformin
alone
(n = 435)

Statin alone
(n = 5786)

Metformin+statin
(n = 1911)

6043 (48)

2350 (51)

222 (51)

2633 (46)

838 (44)

P

Adjusted
Pe

Abbreviations: NC, not calculated; PSA, prostate-specific antigen.
a

Reflecting a percentage of high school education.

b

Indicating that the state pays part or all of the patient's medicare part B premium or the person is in the Medicaid program.

c

1 year to 1 month before cancer diagnosis.

d
e

Within 1 year of cancer diagnosis.

Reflects differences between groups after adjusting for propensity score for metformin, statin, and dual users.

*P < 0.05, compared to neither users.
**P < 0.01, compared to neither users.

TABLE 2

diagnostic users

Hazard ratios (HRs) of all-causes and PCa mortality for metformin and/or statin use in the whole population or pre- and postAll-cause mortality

PCa mortality

Crude HR
(95% CI)

Adjusted HR
(95% CI)a

Crude HR
(95% CI)

Adjusted HR
(95% CI)a

No metformin/no statin

1.0

1.0

1.0

1.0

Metformin alone

1.00 (0.85-1.17)

0.89 (0.75-1.05)

0.71 (0.51-1.00)

0.75 (0.53-1.05)

Statin alone

0.81 (0.75-0.86)**

0.89 (0.83-0.96)**

0.63 (0.55-0.72)**

0.80 (0.69-0.92)**

Metformin+statin

0.69 (0.63-0.76)**

0.75 (0.67-0.83)**

0.45 (0.36-0.55)**

0.64 (0.51-0.81)**

No metformin/no statin

1.0

1.0

1.0

1.0

Metformin alone

1.08 (0.89-1.31)

0.91 (0.75-1.11)

0.75 (0.50-1.11)

0.76 (0.50-1.13)

Statin alone

0.87 (0.82-0.94)**

0.94 (0.87-1.02)

0.69 (0.61-0.79)**

0.84 (0.73-0.98)*

Metformin+statin

0.77 (0.69-0.86)**

0.82 (0.72-0.92)**

0.52 (0.41-0.66)**

0.73 (0.56-0.95)**

No metformin/no statin

1.0

1.0

1.0

1.0

Metformin alone

0.85 (0.64-1.13)

0.89 (0.67-1.19)

0.65 (0.36-1.18)

0.73 (0.39-1.35)

Statin alone

0.57 (0.50-0.64)**

0.73 (0.64-0.84)**

0.38 (0.28-0.51)**

0.58 (0.43-0.78)**

Metformin+statin

0.56 (0.48-0.66)**

0.68 (0.57-0.80)**

0.31 (0.21-0.47)**

0.46 (0.30-0.69)**

Category
All study population

Pre-diagnostic users

Post-diagnostic users

a
Adjusted for cancer stage, ADT, radiation therapy, surgery, salvage radiation, secondary cancer therapy, propensity scores, and imbalanced variables after propensity
scores adjustment.

*P < .05, compared to controls.
**P < .01, compared to controls.

evidence, a well-designed clinical trial is warranted to investigate the roles of statins and combination statins/metformin
to reduce the mortality of PCa.
Several epidemiological studies have previously investigated the association between statin use and all-cause or
PCa mortality, with encouraging though mixed findings. We
observed that use of statin alone or in combination with metformin was significantly associated with reduced all-cause and
PCa mortality. This finding is comparable with the results from

several recent publications. For example, a large retrospective
cohort study with 249.986 Saskatchewan Men aged ≥40 years
reported a substantial protective association between statin use
and PCa mortality (HR, 0.73; 95% CI, 0.66-0.81).26 Wu et al
reported that compare to non-users, statin use was associated
with significant reductions in all-cause mortality (HR, 0.75;
95% CI, 0.68-0.82) and PCa mortality (HR, 0.77; 95% CI,
0.69-0.86) in locally advanced and metastatic PCa patients.27
In addition, using national Veterans Health Administration
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TABLE 3

Hazard ratios for the
association between statin use (name, type,
and potency) and PCa mortality among postdiagnostic users

|

No. of statin users
vs Non-users

Crude HR
(95% CI)

Adjusted HR
(95% CI)a

Atorvastatin

350/5003

0.61 (0.52-0.73)**

0.76 (0.63-0.91)**

Lovastatin

78/5003

0.96 (0.79-1.15)

0.92 (0.76-1.12)

Pravastatin

282/5003

0.53 (0.41-0.69)**

0.68 (0.52-0.89)**

Rosuvastatin

120/5003

0.51 (0.36-0.70)**

0.71 (0.50-0.99)*

Simvastatin

865/5003

0.73 (0.64-0.83)**

0.87 (0.75-0.99)*

Lipophilic

1165/5003

0.68 (0.60-0.76)**

0.85 (0.74-0.97)*

Hydrophilic

385/5003

0.50 (0.40-0.62)**

0.69 (0.55-0.85)**

Low

353/5003

0.61 (0.54-0.69)**

0.83 (0.72-0.95)**

High

1185/5003

0.79 (0.68-0.93)**

0.86 (0.73-1.01)

Category

9

Brand nameb,c

b

Type

b

Potency

a

Adjusted for cancer stage, ADT, radiation therapy, surgery, salvage radiation, secondary cancer therapy,
propensity scores, imbalanced variables after propensity scores adjustment, and metformin use.
b
c

Categories are not mutually exclusive for these variables.

One patient with fluvastatin were excluded from the analysis.

*P < .05, compared to non-statin users.
**P < .01, compared to non-statin users.

database, Anderson-Carter et al identified 87 346 PCa patients
on ADT and found that statin use was an independent predictor
of improved overall survival (HR, 0.66; 95% CI, 0.63-0.68)
and PCa specific survival (HR, 0.56; 95% CI, 0.53-0.60).28
However, several prior studies did not show an association
between this medication and prostate cancer mortality.29-31
This discrepancy may be due to the different study population
across these studies, indicating the findings may apply to clinical heterogeneous of PCa patients. Only two studies aimed
to examine the combination effect of metformin and statin on
prostate cancer outcomes.11,32 One study showed the combination leads to synergistic effects to lower risk of biochemical
recurrence after radical prostatectomy,11 but the other showed
negative results.32 To the best of our knowledge, this is the first
study distinguishing the individual and joint effects of statins
and metformin on all-cause and PCa mortality in high-risk
PCa patients.
We also found that post-diagnostic statin use was associated with lower PCa mortality compared to pre-diagnostic
statin use. A recent population-based cohort study consisting
of a general male population of Finland participating in the
Finnish Randomized Study for PCa Screening showed that
post-diagnosis statin use but not pre-diagnostic statin use was
significantly associated with a decreased risk of PCa death.33
Additionally, Larsen et al reported that post-diagnostic statin
use was associated with a 19% reduction in all-cause mortality and 17% reduction in PCa mortality among 31 790
Danish PaCA patients. 9 However, these studies did not focus
on high-risk patients and did not adjust for metformin effect.
Our finding differs from a published study by Yu et al, which

found that decreased risk of PCa mortality was more pronounced when patients used statins both before and after cancer diagnosis.34 The discrepancy might stem from differences
in study populations and data sources (the study by Yu et al
did not include cancer stage, Gleason grade, or PSA in most
of the patients).
Our study also revealed that men took atorvastatin,
pravastatin, or rosuvastatin, but not lovastatin demonstrated
a significant reduction in PCa mortality compared with
non-users, which is consistent with the findings from a recent population-based cohort study using Taiwan National
Health Insurance Research Data.27 We have only one patient with fluvastatin and no patient with pitavastatin in our
study, therefore no statistic survival analysis is available for
the fluvastatin and with pitavastatin. It has been shown that
that atorvastatin, pravastatin, and rosuvastatin are more effective at lowering triglycerides and low-density lipoprotein
cholesterol and raising high-density lipoprotein cholesterol
than other statins in patient with hypercholesterolemia.35,36
Interestingly, use of atorvastatin was associated with a reduction in PCa mortality (HR, 0.76; 95% CI, 0.63-0.91),
which is consistent with a recent study demonstrating that
men on atorvastatin had a longer median time to progression on androgen deprivation therapy compared to non-users (27.5 vs 17.4 months, P = .0005).37 The in vitro study
further demonstrated that atorvastatin competitively reduced
dehydroepiandrosterone sulfate uptake and thus, effectively
decreased the available intratumoral androgen pool, affording
a plausible mechanism to support the clinical observation.37
Although the exact mechanisms remain unknown, it is worth

10

|

  

TAN et al.

noting that atorvastatin exhibits one of the most potent lipid-lowering effects per dose of any statin, one of the greatest
bioavailability, and one of the longest half-lives.38
Our findings likely apply to most PCa patients because
of the broad representation of various racial/ethnic groups
in this study. The findings may be limited; however, by
the data sources. The SEER-Medicare database contains
limited data on men under age 65. Given that the majority
of PCa is diagnosed among patients who are over age 65,
our findings likely apply to most PCa patients. It is possible that some of the non-users might have used statins
or metformin prior to 2007, the earliest year of available
Part D data. It is worth noting that post-diagnostic users
are much less likely to be affected by prevalent user effect
because we have more than one year of claims to verify
the use of metformin or statins. Therefore, it is unlikely
the misclassification could explain away the large effect
observed in post-diagnostic patients. While immortal time
bias might occur among post-diagnostic users because they
need to live long enough to start medications. However,
we have used the following approaches to minimize its effects. First, we restricted to the study population to those
who survived at least 6 months so that the probability of
initiating metformin or statin after PCa diagnosis is about
the same across groups. Second, we made adjustment to
propensity scores, which estimate the probability of being
one of four exclusive treatment groups, to account for the
confounding effects associated with various patient characteristics or disease status. Lastly, we aligned their follow-up time according to time origin for PCa diagnosis so
that comparisons are being made across persons at equal
distance from time origin. SEER-Medicare files also lack
data on some important confounding variables, including
body mass index, smoking, family history of cancer, or use
of nonsteroidal anti-inflammatory drugs, but subgroup and
sensitivity analyses showed that our results are relatively
robust (Tables S1-S5).39 It is worth noting that dual users
of metformin and statin had higher comorbidity scores at
the baseline vs non-users and this might have led to underestimated treatment benefits. Finally, the impact of the drug
exposure may not be fully captured and limited sample size
of metformin monotherapy users. However, by focusing on
high-risk patients, our study showed clinically meaningful
differences in PCa mortality in various sub-groups.
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CO NC LU S ION

Our data demonstrated that statin alone is associated with reduced all-cause and PCa mortality, and combination of metformin and statin holds great promise for reducing all-cause or
PCa mortality among patients with high-risk PCa, particularly
in post-diagnostic settings. Further sub-analyses revealed that

all brand of statins, except lovastatin, were significantly associated with the reduction in PCa mortality, and the effects of
lipophilic vs hydrophilic and high vs low potency statins were
not statistically different. The data presented in this paper provide crucial insight for the design of future randomized clinical trials of statin for high-risk PCa patients.
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